As the affinity of the H2 cys-diabody and H2 minibody for c-MET are comparable to that of onartuzumab, this is probably due to the high molecular weight of 89Zr-onartuzumab that results in slower blood clearance and prolonged tumour exposure [10, 20]. The gene discussed is MET; the disease is neoplasm.